AI-generated summary
The authors studied intratumoral radioactive gold nanoparticles (198AuNPs), alone and combined with red laser light, in mice with triple-negative breast cancer. They report that nanobrachytherapy alone reduced tumor growth, lung metastases and splenomegaly, with reduced Galectin-3 expression, and that adding laser light gave no additional benefit. The study used a murine model, which limits direct application to humans.
- Who or what was studied
- Female mice inoculated with 4T1 triple-negative breast cancer cells
- Limits stated in the abstract
- The study was conducted in a murine model, so its findings may not apply directly to humans.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Nanobrachytherapy (NB) uses radioactive nanoparticles (NPs) to deliver localized ionizing radiation within tumors, whereas photobiomodulation therapy (PBM) employs low-intensity light to modulate cellular responses. Here, we evaluated NB alone and combined with PBM using 198AuNPs and red laser irradiation in a murine triple-negative breast cancer (TNBC) model. Female mice were inoculated with 4T1 cells in the lower left mammary fat pad and, once tumors reached ∼0.1 cm3, were assigned to three groups: NB (intratumoral injection of ∼200 μCi 198AuNPs), PBM+NB (single red laser session before NB), and Control (PBS). Tumor progression, clinical signs, spleen mass, and lung metastases were evaluated over 23 days. Galectin-3 (Gal-3) expression was quantified by RT-qPCR, and biodistribution and dose delivery of 198AuNPs were assessed by gamma counting and Monte Carlo simulations. NB significantly reduced tumor growth, lung metastases, and splenomegaly and improved clinical status compared with controls, accompanied by decreased Gal-3 expression. Similar outcomes were observed with PBM+NB, with no additional therapeutic benefit compared with NB alone. Biodistribution confirmed preferential tumor retention of 198AuNPs, which declined over time. The estimated tumor dose rate was ∼9.34 mGy/s, decreasing to ∼4.14 mGy/s after 20 min, consistent with NP diffusion. Environmental dose estimates in the isolator remained below 34% of the tumor dose, supporting procedural safety with appropriate radiological protection. These findings demonstrate that 198Au-based NB effectively reduces tumor progression and metastatic burden in TNBC. Under the conditions tested, PBM did not modify therapeutic outcomes. The results support further investigation of localized radionuclide delivery using metallic NPs as an intratumoral radiation strategy.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Dose, Laser, Photobiomodulation therapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.